Ugur Balaban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ugur Balaban has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Kutay Demirkan
Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye
8 shared publications - Emre Kara
Hacettepe University
3 shared publications - Nadir Yalçın
Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University
3 shared publications Burcu Kelleci Cakir
Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye
2 shared publications- Ebru Ortac Ersoy
Division of Intensive Care Medicine, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Türkiye
2 shared publications - Esat Kivanc Kaya
Division of Intensive Care Medicine, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Türkiye
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Critical Care
Clinical pharmacist services in adult intensive care units (PHARM-ICU): an ESICM-endorsed international survey
- 10 November 2026
- Published by Springer Nature in Critical Care
Open AccessClinical pharmacist services in adult intensive care units (PHARM-ICU): an ESICM-endorsed international survey
- Open Access
- 4 July 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Association of stress hyperglycemia ratio with malnutrition, sarcopenia, and frailty in older adults: a cross-sectional study
Stress hyperglycemia ratio (SHR), calculated using admission glucose and glycated hemoglobin (HbA1c), has emerged as a marker of acute metabolic stress and adverse outcomes. However, its relationship with major geriatric syndromes remains unclear. This study investigated the association between SHR and malnutrition, sarcopenia, and frailty in older adults attending a geriatric outpatient clinic. This retrospective cross-sectional study included patients aged ≥ 65 years who underwent comprehensive geriatric assessment between January 2022 and January 2026. SHR was calculated as admission glucose divided by estimated average glucose derived from HbA1c and categorized into quartiles. Malnutrition was assessed using the Mini Nutritional Assessment-Short Form (MNA-SF), probable sarcopenia risk using the SARC-F questionnaire, and frailty using the Clinical Frailty Scale (CFS). Restricted cubic spline analyses and multivariable logistic regression models were performed to evaluate associations between SHR quartiles and geriatric outcomes. A total of 1,401 older adults were included (median age: 73 years [IQR: 69-78]; 66% female). The median SHR was 0.80 (IQR: 0.73-0.89). Restricted cubic spline analyses demonstrated significant nonlinear associations between SHR and geriatric outcomes, with lower SHR values associated with higher odds of malnutrition, probable sarcopenia, and frailty. In fully adjusted analyses, low SHR remained independently associated with probable sarcopenia (OR: 1.51, 95% CI: 1.02-2.25; p = 0.040) and frailty (OR: 1.62, 95% CI: 1.05-2.50; p = 0.031), whereas the association with malnutrition was no longer significant. Associations were more pronounced among participants without diabetes, particularly for probable sarcopenia (p for interaction = 0.038). Lower SHR values were associated with increased vulnerability to geriatric syndromes, particularly probable sarcopenia and frailty, in older adults. These findings suggest that SHR may reflect impaired metabolic adaptation and reduced physiological reserve in aging populations. Further prospective studies are needed to establish the clinical utility of SHR as a marker of geriatric vulnerability.
- 4 July 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Open AccessAssociation of stress hyperglycemia ratio with malnutrition, sarcopenia, and frailty in older adults: a cross-sectional study
Stress hyperglycemia ratio (SHR), calculated using admission glucose and glycated hemoglobin (HbA1c), has emerged as a marker of acute metabolic stress and adverse outcomes. However, its relationship with major geriatric syndromes remains unclear. This study investigated the association between SHR and malnutrition, sarcopenia, and frailty in older adults attending a geriatric outpatient clinic. This retrospective cross-sectional study included patients aged ≥ 65 years who underwent comprehensive geriatric assessment between January 2022 and January 2026. SHR was calculated as admission glucose divided by estimated average glucose derived from HbA1c and categorized into quartiles. Malnutrition was assessed using the Mini Nutritional Assessment-Short Form (MNA-SF), probable sarcopenia risk using the SARC-F questionnaire, and frailty using the Clinical Frailty Scale (CFS). Restricted cubic spline analyses and multivariable logistic regression models were performed to evaluate associations between SHR quartiles and geriatric outcomes. A total of 1,401 older adults were included (median age: 73 years [IQR: 69-78]; 66% female). The median SHR was 0.80 (IQR: 0.73-0.89). Restricted cubic spline analyses demonstrated significant nonlinear associations between SHR and geriatric outcomes, with lower SHR values associated with higher odds of malnutrition, probable sarcopenia, and frailty. In fully adjusted analyses, low SHR remained independently associated with probable sarcopenia (OR: 1.51, 95% CI: 1.02-2.25; p = 0.040) and frailty (OR: 1.62, 95% CI: 1.05-2.50; p = 0.031), whereas the association with malnutrition was no longer significant. Associations were more pronounced among participants without diabetes, particularly for probable sarcopenia (p for interaction = 0.038). Lower SHR values were associated with increased vulnerability to geriatric syndromes, particularly probable sarcopenia and frailty, in older adults. These findings suggest that SHR may reflect impaired metabolic adaptation and reduced physiological reserve in aging populations. Further prospective studies are needed to establish the clinical utility of SHR as a marker of geriatric vulnerability.
- Top Cited PapersOpen Access
- 6 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Performance of large language models on the Turkish Pharmacy Specialty Examination: a comparative analysis of accuracy, confidence, and readability
Large language models (LLMs) have demonstrated strong performance in answering knowledge-based questions in healthcare education. Specialty examinations offer a standardized and objective framework to assess these capabilities. However, to date, no study has evaluated LLM performance on the Turkish Pharmacy Specialty Examination (EUS), a nationally standardized exam applied for the purpose of admitting candidates to pharmacy specialization programs. Therefore, this study aimed to comparatively evaluate LLM performance on EUS questions in terms of accuracy, self-reported confidence, and readability. This study conducted a comparative evaluation of three LLMs-ChatGPT-5.1, DeepSeek-R1, and Gemini 2.5 Flash-using publicly available 84 multiple-choice questions from the EUS between 2017 and 2025. Each question was submitted to each model in a separate, newly initiated session using a standardized prompt. Model performance was assessed based on answer accuracy, self-reported confidence (1-5 scale), and readability of generated responses, using the Flesch reading ease (FRE), gunning fog index (GFI), and simple measure of Gobbledygook (SMOG) indices. All statistical analyses were performed using non-parametric repeated-measures methods, including Cochran's Q test for paired categorical comparisons and the Friedman test with Durbin-Conover post-hoc analyses for readability scores, with two-tailed significance set at p < 0.05. Overall, the evaluated LLMs exhibited high performance. Gemini 2.5 Flash achieved the highest overall accuracy rate (92.9%), followed by ChatGPT-5.1 (90.5%) and DeepSeek-R1 (89.3%), with no statistically significant difference among the models (p = 0.584). Self-reported confidence was predominantly maximal (5/5), with ChatGPT-5.1, DeepSeek-R1, and Gemini 2.5 Flash assigning maximum confidence to 87.5, 55.6, and 66.7% of incorrect responses, respectively. Significant differences in readability were observed among the evaluated LLMs. ChatGPT-5.1 generated texts with lower GFI and SMOG scores compared with DeepSeek-R1 and Gemini 2.5 Flash (p < 0.05), indicating lower linguistic complexity. No statistically significant differences were identified among models for FRE. LLMs demonstrated high and comparable accuracy when answering domain-specific pharmacy examination questions; however, occasional overconfidence in incorrect responses highlights the need for careful oversight. Differences in linguistic complexity underscore the importance of selecting models optimized for readability in educational settings. Overall, these findings suggest that LLMs may have potential as supplementary tools in pharmacy education within examination-based contexts, provided that expert guidance and critical appraisal are maintained to ensure reliability and clarity.
- 6 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Top Cited PapersOpen AccessPerformance of large language models on the Turkish Pharmacy Specialty Examination: a comparative analysis of accuracy, confidence, and readability
Large language models (LLMs) have demonstrated strong performance in answering knowledge-based questions in healthcare education. Specialty examinations offer a standardized and objective framework to assess these capabilities. However, to date, no study has evaluated LLM performance on the Turkish Pharmacy Specialty Examination (EUS), a nationally standardized exam applied for the purpose of admitting candidates to pharmacy specialization programs. Therefore, this study aimed to comparatively evaluate LLM performance on EUS questions in terms of accuracy, self-reported confidence, and readability. This study conducted a comparative evaluation of three LLMs-ChatGPT-5.1, DeepSeek-R1, and Gemini 2.5 Flash-using publicly available 84 multiple-choice questions from the EUS between 2017 and 2025. Each question was submitted to each model in a separate, newly initiated session using a standardized prompt. Model performance was assessed based on answer accuracy, self-reported confidence (1-5 scale), and readability of generated responses, using the Flesch reading ease (FRE), gunning fog index (GFI), and simple measure of Gobbledygook (SMOG) indices. All statistical analyses were performed using non-parametric repeated-measures methods, including Cochran's Q test for paired categorical comparisons and the Friedman test with Durbin-Conover post-hoc analyses for readability scores, with two-tailed significance set at p < 0.05. Overall, the evaluated LLMs exhibited high performance. Gemini 2.5 Flash achieved the highest overall accuracy rate (92.9%), followed by ChatGPT-5.1 (90.5%) and DeepSeek-R1 (89.3%), with no statistically significant difference among the models (p = 0.584). Self-reported confidence was predominantly maximal (5/5), with ChatGPT-5.1, DeepSeek-R1, and Gemini 2.5 Flash assigning maximum confidence to 87.5, 55.6, and 66.7% of incorrect responses, respectively. Significant differences in readability were observed among the evaluated LLMs. ChatGPT-5.1 generated texts with lower GFI and SMOG scores compared with DeepSeek-R1 and Gemini 2.5 Flash (p < 0.05), indicating lower linguistic complexity. No statistically significant differences were identified among models for FRE. LLMs demonstrated high and comparable accuracy when answering domain-specific pharmacy examination questions; however, occasional overconfidence in incorrect responses highlights the need for careful oversight. Differences in linguistic complexity underscore the importance of selecting models optimized for readability in educational settings. Overall, these findings suggest that LLMs may have potential as supplementary tools in pharmacy education within examination-based contexts, provided that expert guidance and critical appraisal are maintained to ensure reliability and clarity.
- Open Access
- 14 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Insights into pharmacogenetic testing in Türkiye: pharmacists’ knowledge, attitudes, and perceived barriers to implementation
Pharmacogenetic (PGx) testing is a key component of precision medicine, supporting individualized drug therapy, improving treatment outcomes, and reducing adverse drug reactions. Pharmacists are central to PGx-guided decision-making; however, their readiness for implementation remains unclear in Türkiye. Identifying current knowledge levels, attitudes, and barriers is essential to inform national strategies for PGx integration into clinical practice. This study aimed to evaluate pharmacists' knowledge, awareness, attitudes, experience, and perceived barriers regarding PGx testing in Türkiye, and to identify predictors of PGx knowledge. A nationwide, web-based cross-sectional survey was conducted between November and December 2025 among pharmacists practicing in diverse settings across Türkiye. A structured questionnaire evaluated pharmacists' PGx-related knowledge and awareness, attitudes, clinical experience, perceived implementation barriers, and training needs. Data were analyzed using descriptive statistics, and multivariable ordinal logistic regression was performed to identify independent predictors of self-rated PGx knowledge. A total of 455 pharmacists participated, mainly community pharmacists (44.2%) and hospital pharmacists (37.8%), with clinical pharmacists representing 9.5%. Although 72.5% were familiar with PGx, only 8.8% had received PGx-related education, and 37.8% self-rated their knowledge as poor. Familiarity with PGx resources and gene-drug knowledge scores were similarly low. Attitudes toward PGx were highly positive, particularly regarding dose optimization and reducing adverse drug reactions. However, real-world experience remained scarce, with only 5.9% having recommended PGx testing and just 4% having made PGx-guided therapeutic recommendations. Insufficient knowledge and awareness emerged as the primary barrier to PGx implementation in practice (47.9%), followed by testing cost (26.2%) and limited trained personnel availability (14.3%). Regression analysis indicated that prior PGx education, postgraduate qualifications, and being a clinical pharmacist significantly predicted higher self-rated PGx knowledge, while age, gender, and years of experience showed no association. Notably, 92.5% expressed willingness to pursue PGx training. Pharmacists in Türkiye hold positive views toward PGx but demonstrate limited knowledge and real-life involvement. Expanding education, integrating PGx into pharmacy curricula, and developing national guidelines and implementation strategies may improve PGx adoption and support personalized pharmacotherapy.
- 14 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessInsights into pharmacogenetic testing in Türkiye: pharmacists’ knowledge, attitudes, and perceived barriers to implementation
Pharmacogenetic (PGx) testing is a key component of precision medicine, supporting individualized drug therapy, improving treatment outcomes, and reducing adverse drug reactions. Pharmacists are central to PGx-guided decision-making; however, their readiness for implementation remains unclear in Türkiye. Identifying current knowledge levels, attitudes, and barriers is essential to inform national strategies for PGx integration into clinical practice. This study aimed to evaluate pharmacists' knowledge, awareness, attitudes, experience, and perceived barriers regarding PGx testing in Türkiye, and to identify predictors of PGx knowledge. A nationwide, web-based cross-sectional survey was conducted between November and December 2025 among pharmacists practicing in diverse settings across Türkiye. A structured questionnaire evaluated pharmacists' PGx-related knowledge and awareness, attitudes, clinical experience, perceived implementation barriers, and training needs. Data were analyzed using descriptive statistics, and multivariable ordinal logistic regression was performed to identify independent predictors of self-rated PGx knowledge. A total of 455 pharmacists participated, mainly community pharmacists (44.2%) and hospital pharmacists (37.8%), with clinical pharmacists representing 9.5%. Although 72.5% were familiar with PGx, only 8.8% had received PGx-related education, and 37.8% self-rated their knowledge as poor. Familiarity with PGx resources and gene-drug knowledge scores were similarly low. Attitudes toward PGx were highly positive, particularly regarding dose optimization and reducing adverse drug reactions. However, real-world experience remained scarce, with only 5.9% having recommended PGx testing and just 4% having made PGx-guided therapeutic recommendations. Insufficient knowledge and awareness emerged as the primary barrier to PGx implementation in practice (47.9%), followed by testing cost (26.2%) and limited trained personnel availability (14.3%). Regression analysis indicated that prior PGx education, postgraduate qualifications, and being a clinical pharmacist significantly predicted higher self-rated PGx knowledge, while age, gender, and years of experience showed no association. Notably, 92.5% expressed willingness to pursue PGx training. Pharmacists in Türkiye hold positive views toward PGx but demonstrate limited knowledge and real-life involvement. Expanding education, integrating PGx into pharmacy curricula, and developing national guidelines and implementation strategies may improve PGx adoption and support personalized pharmacotherapy.
- 10 March 2026
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 93, 102420
Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients
- 10 March 2026
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 93, 102420
Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients
- Open Access
- 6 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Optimizing critical care pharmacotherapy: dynamic prospective evaluation of the medication regimen complexity–intensive care unit (MRC-ICU) score in critically ill patients
Medication regimens in critically ill patients are generally complex, increasing the risk of drug-related problems (DRPs) and unfavorable outcomes. This study aimed to evaluate associations between medication complexity and clinical pharmacist (CP) interventions as well as clinical outcomes using the Medication Regimen Complexity–Intensive Care Unit (MRC-ICU) scoring tool. This prospective cohort study was conducted between June 2024 and April 2025 in a medical ICU of a tertiary university hospital. Throughout the study period, medication regimen complexity was assessed daily. CP interventions were systematically documented, and their potential impact was evaluated using the Clinical, Economic and Organizational (CLEO) tool. A total of 202 patients over 2,287 patient-days were evaluated, during which 748 CP interventions were performed. The number of identified DRPs and CP interventions was significantly higher in patients with high MRC-ICU scores (≥ 8) (p < 0.001), among whom interventions with a moderate clinical impact (p < 0.001) and cost-decreasing economic impact (p = 0.002) were also more frequently observed. The MRC-ICU score at 24 h correlated with the number of CP interventions (r = 0.554; p < 0.001). Multivariable regression analysis revealed each one-point increase in the MRC-ICU score at 24 h was associated with a 3.9% increase in the number of CP interventions [incidence rate ratio (IRR): 1.039; p < 0.001]. According to the patient-day analysis, each one-point increase in the daily MRC-ICU score was associated with an 8.4% increase in daily interventions (IRR: 1.084; p < 0.001). Additionally, strong correlations were observed between the MRC-ICU score and the Acute Physiology and Chronic Health Evaluation II (APACHE II) (r = 0.618), the Sequential Organ Failure Assessment (SOFA) (r = 0.720), and the Modified Nutrition Risk in the Critically Ill (mNUTRIC) (r = 0.614) (for all p < 0.001). Furthermore, the MRC-ICU score demonstrated good predictive performance for ICU mortality, with an area under the curve (AUC) of 0.813. The MRC-ICU score stands out not only as a tool to evaluate regimen complexity but also as a valuable and dynamic instrument for predicting the need for CP interventions, supporting patient prioritization, and integrating with clinical risk scoring systems.
- 6 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessOptimizing critical care pharmacotherapy: dynamic prospective evaluation of the medication regimen complexity–intensive care unit (MRC-ICU) score in critically ill patients
Medication regimens in critically ill patients are generally complex, increasing the risk of drug-related problems (DRPs) and unfavorable outcomes. This study aimed to evaluate associations between medication complexity and clinical pharmacist (CP) interventions as well as clinical outcomes using the Medication Regimen Complexity–Intensive Care Unit (MRC-ICU) scoring tool. This prospective cohort study was conducted between June 2024 and April 2025 in a medical ICU of a tertiary university hospital. Throughout the study period, medication regimen complexity was assessed daily. CP interventions were systematically documented, and their potential impact was evaluated using the Clinical, Economic and Organizational (CLEO) tool. A total of 202 patients over 2,287 patient-days were evaluated, during which 748 CP interventions were performed. The number of identified DRPs and CP interventions was significantly higher in patients with high MRC-ICU scores (≥ 8) (p < 0.001), among whom interventions with a moderate clinical impact (p < 0.001) and cost-decreasing economic impact (p = 0.002) were also more frequently observed. The MRC-ICU score at 24 h correlated with the number of CP interventions (r = 0.554; p < 0.001). Multivariable regression analysis revealed each one-point increase in the MRC-ICU score at 24 h was associated with a 3.9% increase in the number of CP interventions [incidence rate ratio (IRR): 1.039; p < 0.001]. According to the patient-day analysis, each one-point increase in the daily MRC-ICU score was associated with an 8.4% increase in daily interventions (IRR: 1.084; p < 0.001). Additionally, strong correlations were observed between the MRC-ICU score and the Acute Physiology and Chronic Health Evaluation II (APACHE II) (r = 0.618), the Sequential Organ Failure Assessment (SOFA) (r = 0.720), and the Modified Nutrition Risk in the Critically Ill (mNUTRIC) (r = 0.614) (for all p < 0.001). Furthermore, the MRC-ICU score demonstrated good predictive performance for ICU mortality, with an area under the curve (AUC) of 0.813. The MRC-ICU score stands out not only as a tool to evaluate regimen complexity but also as a valuable and dynamic instrument for predicting the need for CP interventions, supporting patient prioritization, and integrating with clinical risk scoring systems.
- Open Access
- 28 July 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 1-11
Assessment of nutritional indices for predicting clinical outcomes in critically ill elderly patients: a prospective cohort study
Malnutrition is a prevalent issue in critically ill elderly patients and is closely linked to poor clinical outcomes. This study aimed to assess the prognostic value of four nutritional indices—modified nutrition risk in the critically ill (mNUTRIC), Geriatric Nutritional Risk Index (GNRI), hemoglobin, albumin, lymphocyte, and platelet (HALP), and neutrophil-to-lymphocyte ratio (NLR)—in predicting intensive care unit (ICU) outcomes. This prospective cohort study included elderly patients (aged ≥ 65 years) who were admitted to the medical ICU of a tertiary care university hospital. Nutritional indices (mNUTRIC, GNRI, HALP, and NLR) were evaluated for their prognostic value in predicting 28-day mortality, ICU mortality, and ICU length of stay (LOS) using multivariable regression and receiver operating characteristic (ROC) curve analyses. Seventy-three patients were included, with a median age (interquartile range) of 74 (10) years and 56.2% male. The mNUTRIC score was identified as an independent risk factor for 28-day mortality (OR = 2.505, 95%CI: 1.164–5.391, p = 0.019) and ICU mortality (OR = 2.736, 95%CI: 1.350–5.545, p = 0.005), with strong predictive performance (AUC: 0.864 and 0.858, respectively). It was also associated with prolonged ICU LOS (RR = 1.117, 95% CI: 1.033–1.207, p = 0.005). While GNRI exhibited good predictive performance (AUC: 0.811 and 0.799 for 28-day mortality and ICU mortality, respectively), it was not an independent factor. In contrast, HALP and NLR showed limited prognostic value for mortality. The mNUTRIC score was identified as the strongest prognostic tool, with GNRI also demonstrating considerable predictive value for mortality outcomes, enhancing nutritional risk screening and clinical decision-making in elderly ICU patients.
- 28 July 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 1-11
Open AccessAssessment of nutritional indices for predicting clinical outcomes in critically ill elderly patients: a prospective cohort study
Malnutrition is a prevalent issue in critically ill elderly patients and is closely linked to poor clinical outcomes. This study aimed to assess the prognostic value of four nutritional indices—modified nutrition risk in the critically ill (mNUTRIC), Geriatric Nutritional Risk Index (GNRI), hemoglobin, albumin, lymphocyte, and platelet (HALP), and neutrophil-to-lymphocyte ratio (NLR)—in predicting intensive care unit (ICU) outcomes. This prospective cohort study included elderly patients (aged ≥ 65 years) who were admitted to the medical ICU of a tertiary care university hospital. Nutritional indices (mNUTRIC, GNRI, HALP, and NLR) were evaluated for their prognostic value in predicting 28-day mortality, ICU mortality, and ICU length of stay (LOS) using multivariable regression and receiver operating characteristic (ROC) curve analyses. Seventy-three patients were included, with a median age (interquartile range) of 74 (10) years and 56.2% male. The mNUTRIC score was identified as an independent risk factor for 28-day mortality (OR = 2.505, 95%CI: 1.164–5.391, p = 0.019) and ICU mortality (OR = 2.736, 95%CI: 1.350–5.545, p = 0.005), with strong predictive performance (AUC: 0.864 and 0.858, respectively). It was also associated with prolonged ICU LOS (RR = 1.117, 95% CI: 1.033–1.207, p = 0.005). While GNRI exhibited good predictive performance (AUC: 0.811 and 0.799 for 28-day mortality and ICU mortality, respectively), it was not an independent factor. In contrast, HALP and NLR showed limited prognostic value for mortality. The mNUTRIC score was identified as the strongest prognostic tool, with GNRI also demonstrating considerable predictive value for mortality outcomes, enhancing nutritional risk screening and clinical decision-making in elderly ICU patients.
- 24 July 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 818-825
Posaconazole Therapeutic Drug Monitoring in Daily Practice: A Single-Center Analysis
Purpose Posaconazole plasma levels can vary considerably among patients, underscoring the need for therapeutic drug monitoring (TDM). Nevertheless, access to TDM is limited in many clinical settings. This study aimed to investigate the impact of posaconazole TDM in daily practice at a tertiary care hospital. Methods We conducted a single-center retrospective study at a university hospital, reviewing patients who received posaconazole delayed-release tablets and underwent TDM between January 1, 2022, and December 18, 2023. Results A total of 35 patients with 74 posaconazole TDM were evaluated. Twenty-seven (77.1%) patients received posaconazole for prophylaxis. The median plasma concentration of posaconazole was 1.45 mg/L (interquartile range [IQR]: 1.74 mg/L). Overall, 74.3% of posaconazole concentrations were within the target range. Target attainment was achieved in 75.9% of prophylactic measurements (> 0.7 mg/L) and 68.7% of treatment measurements (> 1 mg/L). Subtherapeutic levels were identified in 19 samples from 12 patients. Among eight patients receiving prophylactic posaconazole with trough levels below 0.7 mg/L, two experienced breakthrough invasive fungal infections. Diarrhea, sampling before steady state, medication non-adherence, and poor oral intake were significantly more frequent in cases with subtherapeutic posaconazole levels (p = 0.022). Among six measurements with posaconazole concentrations exceeding 3.75 mg/L, an adverse effect attributable to posaconazole was observed in only one of the five patients with these elevated levels. Conclusion The findings of this real-world assessment suggest that posaconazole TDM may play a critical role in optimizing both prophylaxis and treatment, particularly among patients at risk for subtherapeutic exposure.
- 24 July 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 818-825
Posaconazole Therapeutic Drug Monitoring in Daily Practice: A Single-Center Analysis
Purpose Posaconazole plasma levels can vary considerably among patients, underscoring the need for therapeutic drug monitoring (TDM). Nevertheless, access to TDM is limited in many clinical settings. This study aimed to investigate the impact of posaconazole TDM in daily practice at a tertiary care hospital. Methods We conducted a single-center retrospective study at a university hospital, reviewing patients who received posaconazole delayed-release tablets and underwent TDM between January 1, 2022, and December 18, 2023. Results A total of 35 patients with 74 posaconazole TDM were evaluated. Twenty-seven (77.1%) patients received posaconazole for prophylaxis. The median plasma concentration of posaconazole was 1.45 mg/L (interquartile range [IQR]: 1.74 mg/L). Overall, 74.3% of posaconazole concentrations were within the target range. Target attainment was achieved in 75.9% of prophylactic measurements (> 0.7 mg/L) and 68.7% of treatment measurements (> 1 mg/L). Subtherapeutic levels were identified in 19 samples from 12 patients. Among eight patients receiving prophylactic posaconazole with trough levels below 0.7 mg/L, two experienced breakthrough invasive fungal infections. Diarrhea, sampling before steady state, medication non-adherence, and poor oral intake were significantly more frequent in cases with subtherapeutic posaconazole levels (p = 0.022). Among six measurements with posaconazole concentrations exceeding 3.75 mg/L, an adverse effect attributable to posaconazole was observed in only one of the five patients with these elevated levels. Conclusion The findings of this real-world assessment suggest that posaconazole TDM may play a critical role in optimizing both prophylaxis and treatment, particularly among patients at risk for subtherapeutic exposure.
- Open Access
- 21 July 2025
- Published by Springer Nature in BMC Medical Education
- Vol. 25 (1) , 1
Correction: Assessment of food-drug interaction knowledge among Turkish healthcare professionals
- 21 July 2025
- Published by Springer Nature in BMC Medical Education
- Vol. 25 (1) , 1
Open AccessCorrection: Assessment of food-drug interaction knowledge among Turkish healthcare professionals